Targeting bone morphogenetic protein signaling on renal and vascular diseases

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 1, 2010, Pages 26-31

  MacIel, Thiago T ^a,b   Kempf, Hervé ^a,b   Campos, Alexandre H ^c  

^a INSERM   (France)

^b l'alimentation et l'Environnement   (France)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Bone morphogenetic protein; Kidney; Pathophysiology; Vasculature

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

ADULT; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; DIABETIC NEUROPATHY; ENDOTHELIUM CELL; HUMAN; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FIBROSIS; LOSS OF FUNCTION MUTATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; HUMANS; HYPERTENSION, PULMONARY; KIDNEY DISEASES; SIGNAL TRANSDUCTION; TUNICA INTIMA; VASCULAR DISEASES;

EID: 73849131053     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328332fc13     Document Type: Review

References (72)

1. Blitz IL, Cho KW. Finding partners: how BMPs select their targets. Dev Dyn 2009; 238:1321-1331.
2. Nohe A, Keating E, Knaus P, et al. Signal transduction of bone morphogenetic protein receptors. Cell Signal 2004; 16:291-299.
3. Park SH. Fine tuning and cross-talking of TGF-beta signal by inhibitory Smads. J Biochem Molec Biol 2005; 38:9-16.
4. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006; 7 (1-2):51-65.
5. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biological Chem 2002; 277:4388-4394.
6. Kirkbride KC, Townsend TA, Bruinsma MW, et al. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 2008; 283:7628-7637.
7. Kanomata K, Kokabu S, Nojima J, et al. DRAGON, a GPI-anchored membrane protein, inhibits BMP signaling in C2C12 myoblasts. Genes Cells 2009; 14:695-702.
8. Zouvelou V, Passa O, Segklia K, et al. Generation and functional characterization of mice with a conditional BMP7 allele. Int J Develop Biol 2009; 53:597-603.
9. Bandyopadhyay A, Tsuji K, Cox K, et al. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2006; 2:e216.
10. Monteiro RM, de Sousa Lopes SM, Bialecka M, et al. Real time monitoring of BMP Smads transcriptional activity during mouse development. Genesis 2008; 46:335-346.
11. Blank U, Seto ML, Adams DC, et al. An in vivo reporter of BMP signaling in organogenesis reveals targets in the developing kidney. BMC Dev Biol 2008; 8:86.
12. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nature Chem Biol 2008; 4:33-41.
13. Sugimoto H, Grahovac G, Zeisberg M, et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56:1825-1833.
14. De Petris L, Hruska KA, Chiechio S, et al. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22:3442-3450.
15. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12:2392-2399.
16. Turk T, Leeuwis JW, Gray J, et al. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 2009; 57:623-631.
17. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17:2504-2512.
18. Yeh CH, Chang CK, Cheng MF, et al. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats. Horm Metab Res 2009; 41:605-611.
19. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293:F1641-1648.
20. Yeh CH, Chang CK, Cheng MF, et al. The antioxidative effect of bone morphogenetic protein-7 against high glucose-induced oxidative stress in mesangial cells. Biochem Biophys Res Commun 2009; 382:292-297.
21. McMahon R, Murphy M, Clarkson M, et al. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. J Biological Chem 2000; 275:9901-9904.
22. Dolan V, Murphy M, Sadlier D, et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 2005; 45:1034-1039.
23. Walsh DW, Roxburgh SA, McGettigan P, et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008; 1782:10-21.
24. Roxburgh SA, Kattla JJ, Curran SP, et al. Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 2009; 58:1641-1650.
25. Roestenberg P, van Nieuwenhoven FA, Joles JA, et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006; 290:F1344-F1354.
26. Abreu JG, Ketpura NI, Reversade B, et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4:599-604.
27. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008; 19:2098-2107.
28. Xu Y, Wan J, Jiang D, et al. BMP-7 counteracts TGF-beta1-induced epithelialto- mesenchymal transition in human renal proximal tubular epithelial cells. J Nephrol 2009; 22:403-410.
29. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284:F1006-F1013.
30. Motazed R, Colville-Nash P, Kwan JT, et al. BMP-7 and proximal tubule epithelial cells: activation of multiple signaling pathways reveals a novel antifibrotic mechanism. Pharm Res 2008; 25:2440-2446.
31. Vukicevic S, Basic V, Rogic D, et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102:202-214.
32. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9:964-968.
33. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 2000; 279:F130-143.
34. Yang YL, Liu YS, Chuang LY, et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology 2009; 150:727-740.
35. Chan WL, Leung JC, Chan LY, et al. BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int 2008; 74:1026-1039.
36. Yan J, Yang S, Zhang J, et al. BMP6 attenuates oxidant injury in HK-2 cells via Smad-dependent HO-1 induction. Free Radic Biol Med 2009; 46:1275-1282.
37. Carvajal G, Droguett A, Burgos ME, et al. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 2008; 40:734-739.
38. Mezzano S, Droguett A, Burgos ME, et al. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 2007; 22:1882-1890.
39. Yanagita M. Balance between bone morphogenetic proteins and their antagonists in kidney injury. Ther Apher Dial 2007; 11(Suppl 1):S38-S43.
40. Tanaka M, Endo S, Okuda T, et al. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int 2008; 73:181-191.
41. Larman BW, Karolak MJ, Adams DC, et al. Chordin-like 1 and twisted gastrulation 1 regulate BMP signaling following kidney injury. J Am Soc Nephrol 2009; 20:1020-1031.
42. Kiyono M, Shibuya M. Inhibitory Smad transcription factors protect arterial endothelial cells from apoptosis induced by BMP4. Oncogene 2006; 25:7131-7137.
43. Nakaoka T, Gonda K, Ogita T, et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 1997; 100:2824-2832.
44. Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP- 2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118:1846-1857.
45. Lagna G, Ku MM, Nguyen PH, et al. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardinrelated transcription factors. J Biol Chem 2007; 282:37244-37255.
46. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184:37-45.
47. Yu PB, Deng DY, Beppu H, et al. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 2008; 283:3877-3888.
48. Maciel TT, Melo RS, Campos AH. The bone morphogenetic protein antagonist gremlin promotes vascular smooth muscle cell apoptosis. J Vasc Res 2009; 46:325-332.
49. Maciel TT, Melo RS, Schor N, et al. Gremlin promotes vascular smooth muscle cell proliferation and migration. J Mol Cell Cardiol 2008; 44:370-379.
50. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006; 3:680-686.
51. Tada Y, Majka S, Carr M, et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1556-1563.
52. West J, Harral J, Lane K, et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008; 295:L744-755.
53. Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005; 96:1053-1063.
54. Yang J, Davies RJ, Southwood M, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008; 102:1212-1221.
55. Yang X, Lee PJ, Long L, et al. BMP4 induces HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary artery myocytes. Am J Respir Cell Mol Biol 2007; 37:598-605.
56. Miriyala S, Gongora Nieto MC, Mingone C, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006; 113:2818-2825.
57. Sorescu GP, Sykes M, Weiss D, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 2003; 278:31128-31135.
58. Csiszar A, Labinskyy N, Jo H, et al. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2008; 295:H569-H577.
59. Bostrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91:1800-1809.
60. Yao Y, Zebboudj AF, Torres A, et al. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc Res 2007; 74:279-289.
61. Chang K, Weiss D, Suo J, et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 2007; 116:1258-1266.
62. Ungvari ZI. Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4. Circulation 2007; 116:1221-1223.
63. Yao Y, Shao ES, Jumabay M, et al. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol 2008; 28:2266-2274.
64. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14:1559-1567.
65. Al-Aly Z, Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27:2589-2596.
66. Towler DA, Shao JS, Cheng SL, et al. Osteogenic regulation of vascular calcification. Ann N Y Acad Sci 2006; 1068:327-333.
67. Hruska KA. Vascular smooth muscle cells in the pathogenesis of vascular calcification. Circ Res 2009; 104:710-711.
68. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104:733-741.
69. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199:271-277.
70. Lagna G, Nguyen PH, Ni W, et al. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1059-L1067.
71. Jara A, Chacon C, Burgos ME, et al. Expression of gremlin, a bone morphogenetic protein antagonist, is associated with vascular calcification in uraemia. Nephrol Dial Transplant 2009; 24:1121-1129.
72. Yao Y, Zebboudj AF, Shao E, et al. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem 2006; 281:33921-33930.